MicroRNA determinants of neuroendocrine differentiation in metastatic castration-resistant prostate cancer

Therapy-induced neuroendocrine prostate cancer (NEPC), an extremely aggressive variant of castration-resistant prostate cancer (CRPC), is increasing in incidence with the widespread use of highly potent androgen receptor (AR)-pathway inhibitors (APIs) such as Enzalutamide (ENZ) and Abiraterone and a...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhagirath, Divya, Liston, Michael, Patel, Nikhil, Akoto, Theresa, Lui, Byron, Yang, Thao Ly, To, Dat My, Majid, Shahana, Dahiya, Rajvir, Tabatabai, Z Laura, Saini, Sharanjot
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718386/
https://www.ncbi.nlm.nih.gov/pubmed/33037409
http://dx.doi.org/10.1038/s41388-020-01493-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718386/
https://www.ncbi.nlm.nih.gov/pubmed/33037409
http://dx.doi.org/10.1038/s41388-020-01493-8

Ejemplares similares